News

Zacks Investment Research on MSN1d
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $5.84, reflecting a +1.83% shift from the previouse trading day's closing. The stock outpaced the S&P 500's ...
Zacks Investment Research on MSN4d
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...